MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2019000428

Медицинская библиотека · Blood · 2019

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.

Yacoub Abdulraheem, Mascarenhas John, Kosiorek Heidi, Prchal Josef T, Berenzon Dmitry, Baer Maria R, Ritchie Ellen, Silver Richard T, Kessler Craig, Winton Elliott, Finazzi Maria Chiara, Rambaldi Alessandro, Vannucchi Alessandro M, Leibowitz David, Rondelli Damiano, Arcasoy Murat O, Catchatourian Rosalind, Vadakara Joseph, Rosti Vittorio, Hexner Elizabeth, Kremyanskaya Marina, Sandy Lonette, Tripodi Joseph, Najfeld Vesna, Farnoud Noushin, Papaemmanuil Elli, Salama Mohamed, Singer-Weinberg Rona, Rampal Raajit, Goldberg Judith D, Barbui Tiziano, Mesa Ruben, Dueck Amylou C, Hoffman Ronald

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To further define the role of rIFN-α, we investigated the outcomes of pegylated-rIFN-α2a (PEG) therapy in ET and PV patients previously treated with hydroxyurea (HU). The Myeloproliferative Disorders Research Consortium (MPD-RC)-111 study was an investigator-initiated, international, multicenter, phase 2 trial evaluating the ability of PEG therapy to induce complete (CR) and partial (PR) hematologic responses in patients with high-risk ET or PV who were either refractory or intolerant to HU. The study included 65 patients with ET and 50 patients with PV. The overall response rates (ORRs; CR/PR) at 12 months were 69.2% (43.1% and 26.2%) in ET patients and 60% (22% and 38%) in PV patients. CR rates were higher in CALR-mutated ET patients (56.5% vs 28.0%; P = .01), compared with those in subjects lacking a CALR mutation. The median absolute reduction in JAK2V617F variant allele fraction was -6% (range, -84% to 47%) in patients achieving a CR vs +4% (range, -18% to 56%) in patients with PR or nonresponse (NR). Therapy was associated with a significant rate of adverse events (AEs); most were manageable, and PEG discontinuation related to AEs occurred in only 13.9% of subjects. We conclude that PEG is an effective therapy for patients with ET or PV who were previously refractory and/or intolerant of HU. This trial was registered at www.clinicaltrials.gov as #NCT01259856.

Для цитирования: Yacoub Abdulraheem, Mascarenhas John, Kosiorek Heidi, Prchal Josef T, Berenzon Dmitry, Baer Maria R, Ritchie Ellen, Silver Richard T, Kessler Craig, Winton Elliott, Finazzi Maria Chiara, Rambaldi Alessandro, Vannucchi Alessandro M, Leibowitz David, Rondelli Damiano, Arcasoy Murat O, Catchatourian Rosalind, Vadakara Joseph, Rosti Vittorio, Hexner Elizabeth, Kremyanskaya Marina, Sandy Lonette, Tripodi Joseph, Najfeld Vesna, Farnoud Noushin, Papaemmanuil Elli, Salama Mohamed, Singer-Weinberg Rona, Rampal Raajit, Goldberg Judith D, Barbui Tiziano, Mesa Ruben, Dueck Amylou C, Hoffman Ronald. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.. Blood. 2019. DOI: 10.1182/blood.2019000428.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.